• Medical
  • Nano
  • Energy
  • Pharma
  • Material
  • Electronics
  • Gadgets

FP88 Vaccine for Multiple Sclerosis and
Other Autoimmune Diseases


Mark Foley
Licensing Associate
Office of Technology Transfer
East Carolina University
2200 South Charles Boulevard
Greenville, NC 27858

Phone: 252-328-9546

Bookmark and Share

East Carolina University Office of Technology Transfer

FP88 Vaccine for Multiple Sclerosis and
Other Autoimmune Diseases

East Carolina University seeks a collaborative partner to develop a new advancement in the treatment and prevention of autoimmune diseases—especially multiple sclerosis (MS).

MS afflicts more than 2.5 million people worldwide. In the United States alone, 400,000 people suffer from the disorder at an annual cost to the economy of about $20 billion. MS is an autoimmune disease that affects the central nervous system, and more particularly, the myelin material that surrounds and protects individual nerve fibers. The body's own immune system attacks the myelin, leaving behind lesions and scarring that interrupt electric impulses traveling to and from the brain. Symptoms of MS include fatigue, bladder and bowel dysfunction, difficulty in walking, reduced cognitive function, dizziness, depression, pain, visual impairment, sexual dysfunction, and other symptoms. No cure exists for MS, but various treatments are available to improve the quality of life for those living with the disease. The global market for these treatments is currently estimated at $4.9 billion.

Mark D. Mannie, PhD, of the Department of Microbiology and Immunology at the Brody School of Medicine at East Carolina University, recently developed a unique fusion protein that, when tested in the rat model of experimental autoimmune encephalomyelitis (EAE), produced a dramatic tolerogenic effect. Rats, whether pretreated or treated following exposure to the EAE stimulating agent, exhibited decreased incidence, reduced symptoms, and delayed onset of attack.

Dr. Mannie is currently planning studies in other mammalian models that will eventually lead to clinical trials in humans.

• Strong market need for products with improved efficacy and simpler modes of delivery
• Technology may be applied to other autoimmune disorders
• Fusion protein is selective and does not hinder normal T cell activity in the immune system

Other Applications:
Diabetes type I
Rheumatoid arthritis
Crohn's disease
Hyperthyroidism and hypothyroidism
Other autoimmune disorders

About The Inventor:
Mark D. Mannie
Professor, Department of Microbiology and Immunology
The Brody School of Medicine at East Carolina University
600 Moye Boulevard
Greenville, NC 27834-4534

Recent Articles:
Mannie, M. D., J. L. Devine, B. A. Clayson, L. T. Lewis, and D. J. Abbott. 2007. Cytokine-neuroantigen fusion proteins:  new tools for modulation of myelin basic protein (MBP)-specific T cell responses in experimental autoimmune encephalomyelitis.  J. Immunol. Methods.  319, 118-32. More.

Mannie, M. D., B. A. Clayson, E. J. Buskirk, J. L. DeVine, J. J. Hernandez, and D. J. Abbott.  2007.  IL-2/ neuroantigen fusion proteins as antigen-specific tolerogens in experimental autoimmune encephalomyelitis (EAE):  correlation of T cell-mediated antigen presentation and tolerance induction.  J. Immunol. 178, 2835-2843. More.

Mannie, M. D. & D. J. Abbott.  2007.  A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis.  J. Immunol. 179, 1458-1465. More.